195 related articles for article (PubMed ID: 38227740)
1. ATR inhibition using gartisertib enhances cell death and synergises with temozolomide and radiation in patient-derived glioblastoma cell lines.
Lozinski M; Bowden NA; Graves MC; Fay M; Day BW; Stringer BW; Tooney PA
Oncotarget; 2024 Jan; 15():1-18. PubMed ID: 38227740
[TBL] [Abstract][Full Text] [Related]
2. Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma.
Ganesa S; Sule A; Sundaram RK; Bindra RS
Sci Rep; 2022 Apr; 12(1):5827. PubMed ID: 35388070
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
4. Contribution of ATM and ATR to the resistance of glioblastoma and malignant melanoma cells to the methylating anticancer drug temozolomide.
Eich M; Roos WP; Nikolova T; Kaina B
Mol Cancer Ther; 2013 Nov; 12(11):2529-40. PubMed ID: 23960094
[TBL] [Abstract][Full Text] [Related]
5. The antagonistic effects of temozolomide and trichostatin a combination on MGMT and DNA mismatch repair pathways in Glioblastoma.
Güven M; Taşpınar F; Denizler-Ebiri FN; Castresana JS; Taşpınar M
Med Oncol; 2023 Jul; 40(8):223. PubMed ID: 37403006
[TBL] [Abstract][Full Text] [Related]
6. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.
Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA
Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
Wu Q; Berglund AE; Macaulay RJ; Etame AB
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological inhibition of serine synthesis enhances temozolomide efficacy by decreasing O
Jin L; Kiang KM; Cheng SY; Leung GK
Lab Invest; 2022 Feb; 102(2):194-203. PubMed ID: 34625658
[TBL] [Abstract][Full Text] [Related]
9. MEX3A Impairs DNA Mismatch Repair Signaling and Mediates Acquired Temozolomide Resistance in Glioblastoma.
Gan T; Wang Y; Xie M; Wang Q; Zhao S; Wang P; Shi Q; Qian X; Miao F; Shen Z; Nie E
Cancer Res; 2022 Nov; 82(22):4234-4246. PubMed ID: 36112059
[TBL] [Abstract][Full Text] [Related]
10. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
[TBL] [Abstract][Full Text] [Related]
12. Up-Regulation of Cyclooxygenase-2 (COX-2) Expression by Temozolomide (TMZ) in Human Glioblastoma (GBM) Cell Lines.
Lombardi F; Augello FR; Artone S; Gugu MK; Cifone MG; Cinque B; Palumbo P
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163465
[TBL] [Abstract][Full Text] [Related]
13. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
[TBL] [Abstract][Full Text] [Related]
14. A co-formulation of interferons type I and II enhances temozolomide response in glioblastoma with unmethylated MGMT promoter status.
Vázquez-Blomquist D; Leenstra S; van der Kaaij M; Villarreal A; Bello-Rivero I
Mol Biol Rep; 2020 Jul; 47(7):5263-5271. PubMed ID: 32607953
[TBL] [Abstract][Full Text] [Related]
15. Influence of MMR, MGMT Promotor Methylation and Protein Expression on Overall and Progression-Free Survival in Primary Glioblastoma Patients Treated with Temozolomide.
Brawanski KR; Sprung S; Freyschlag CF; Hoeftberger R; Ströbel T; Haybaeck J; Thomé C; Manzl C; Birkl-Toeglhofer AM
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047153
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide Sensitizes MGMT-Deficient Tumor Cells to ATR Inhibitors.
Jackson CB; Noorbakhsh SI; Sundaram RK; Kalathil AN; Ganesa S; Jia L; Breslin H; Burgenske DM; Gilad O; Sarkaria JN; Bindra RS
Cancer Res; 2019 Sep; 79(17):4331-4338. PubMed ID: 31273061
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth.
Ramirez YP; Mladek AC; Phillips RM; Gynther M; Rautio J; Ross AH; Wheelhouse RT; Sakaria JN
Mol Cancer Ther; 2015 Jan; 14(1):111-9. PubMed ID: 25351918
[TBL] [Abstract][Full Text] [Related]
18. The effects of tumor treating fields and temozolomide in MGMT expressing and non-expressing patient-derived glioblastoma cells.
Clark PA; Gaal JT; Strebe JK; Pasch CA; Deming DA; Kuo JS; Robins HI
J Clin Neurosci; 2017 Feb; 36():120-124. PubMed ID: 27865821
[TBL] [Abstract][Full Text] [Related]
19. PARP‑1 inhibition sensitizes temozolomide‑treated glioblastoma cell lines and decreases drug resistance independent of MGMT activity and PTEN proficiency.
Montaldi AP; Lima SCG; Godoy PRDV; Xavier DJ; Sakamoto-Hojo ET
Oncol Rep; 2020 Nov; 44(5):2275-2287. PubMed ID: 32901889
[TBL] [Abstract][Full Text] [Related]
20. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Fishman H; Monin R; Dor-On E; Kinzel A; Haber A; Giladi M; Weinberg U; Palti Y
J Neurooncol; 2023 May; 163(1):83-94. PubMed ID: 37131108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
